Brief: AB Science Receives Regulatory Authorization To Commence Second Phase 2 Covid-19 Study

AB Science SA

28/09/2021 18:28

Sept 28 (Reuters) - AB SCIENCE SA  ABS.PA :
    * REG-AB SCIENCE RECEIVES REGULATORY AUTHORIZATION TO
COMMENCE A
SECOND PHASE 2 COVID-19 STUDY
    * AB SCIENCE SA - STUDY DESIGN FOCUSES DIRECTLY ON
MASITINIB'S
ANTIVIRAL ACTIVITY AGAINST COVID-19 VIRUS (SARS-COV-2) FOR
TREATMENT OF PATIENTS AT AN EARLY STAGE OF DISEASE
    * AB SCIENCE SA - WITH TWO PHASE 2 STUDIES, MASITINIB IS A
LEADING
CANDIDATE IN DEVELOPMENT OF ORAL PROTEASE INHIBITORS FOR
TREATMENT OF NON-HOSPITALIZED AND HOSPITALIZED COVID-19 PATIENTS

Source text for Eikon:  ID:nGNE35jSzG 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))